Premature Delivery Clinical Trial
Official title:
Study of New Biomarkers Associated With the Risk of Premature Delivery During Spontaneous Work With Intact Membranes Before 37 Weeks of Amenorrhea.
Despite the progress made in the organization of care and neonatal care, prematurity remains
the main cause of morbidity and perinatal mortality.
This study aims to estimate the prognostic value of new biomarkers (proteomic markers) on the
occurrence of preterm birth.
Despite the progress made in the organization of care and neonatal care, prematurity remains
the main cause of morbidity and perinatal mortality. With 7.2% of premature deliveries in
France, threat of premature labor remains the leading cause of maternal transfer and
hospitalization. In terms of mortality, morbidity and cost, the fight against prematurity
remains a national priority in terms of public health.
The diagnosis of threat of premature labor at high risk of preterm labor is difficult and
clinical and laboratory criteria often remain insufficient. Measurement of the cervix by
endovaginal ultrasound lacks sensitivity and specificity. Among the biological criteria, only
fibronectin, which has a good negative predictive value, is used in current practice. Despite
the use of these two prognostic criteria, only 40% of hospitalized patients will give birth
prematurely.
Recent advances in proteomics allow us to study complex proteomes and compare them.
Preliminary studies already carried out have revealed families of proteins expressed
differently in situations of work or premature delivery. We therefore hypothesize that the
study of a woman's vaginal proteome with threat of premature labor may reveal new markers of
preterm labor. These markers could help the clinician in its therapeutic management and thus
reduce hospitalizations, better target patients requiring tocolytic treatment and optimize
the use of corticosteroids. In addition, variations in the proteome may help to understand
the physiopathological mechanisms of premature delivery, which are necessary for the
development of effective therapeutics.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02904070 -
Interest of Placental Alpha-microglobulin-1 Detection Test to Assess Risk of Premature Delivery in Reunion Island
|
Phase 4 | |
| Terminated |
NCT01977079 -
Procalcitonin and Threatened Premature Delivery
|
N/A | |
| Withdrawn |
NCT02859298 -
Feasibility Study and Predictive Value of the Uterine Cervix Polarimetric Imaging for the Management of the Threat of Premature Delivery.
|
N/A | |
| Not yet recruiting |
NCT06349122 -
Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth
|
Phase 4 |